# A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

> **NCT03393416** · PHASE1 · UNKNOWN · sponsor: **HRYZ Biotech Co.** · enrollment: 28 (estimated)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **BIOLOGICAL:** MASCT-I
- **DRUG:** PD1 antibody

## Key facts

- **NCT ID:** NCT03393416
- **Lead sponsor:** HRYZ Biotech Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-19
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2019-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393416, "A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03393416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*